Terns Pharmaceuticals Inc., trading on NASDAQ under the symbol TERN, has released a corporate presentation highlighting its progress as of June 2025. The company is advancing two differentiated clinical assets, TERN-701 and TERN-601, with significant milestones anticipated in the fourth quarter of 2025. TERN-701, an allosteric BCR-ABL inhibitor, aims to address chronic myeloid leukemia $(CML.UK)$ in a market exceeding $5 billion. Meanwhile, TERN-601, an oral GLP-1 receptor agonist, targets obesity with potential competitive weight loss and superior tolerability. Both programs are progressing through clinical trials, with TERN-701 in Phase 1 and TERN-601 in Phase 2. Terns Pharmaceuticals has secured a cash runway of $334 million to support its development pipeline into 2028. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.